The prognostic significance of early treatment response in pediatric relapsed acute myeloid leukemia: results of the international study Relapsed AML 2001/01
Ursula Creutzig,
Martin Zimmermann,
Michael N. Dworzak,
Brenda Gibson,
Rienk Tamminga,
Jonas Abrahamsson,
Shau-Yin Ha,
Henrik Hasle,
Alexey Maschan,
Yves Bertrand,
Guy Leverger,
Christine von Neuhoff,
Bassem Razzouk,
Carmelo Rizzari,
Petr Smisek,
Owen P. Smith,
Batia Stark,
Dirk Reinhardt,
Gertjan L. Kaspers
Affiliations
Ursula Creutzig
BFM-AML Group, Hannover, c/o Pediatric Hematology/Oncology, Hannover Medical High School, Germany
Martin Zimmermann
BFM-AML Group, Hannover, c/o Pediatric Hematology/Oncology, Hannover Medical High School, Germany
Michael N. Dworzak
BFM-AML Group, St. Anna Children’s Hospital and Children’s Cancer Research Institute, Department of Pediatrics, Medical University of Vienna, Austria
Brenda Gibson
UK NCRI Childhood Leukaemia Group, Department of Paediatric Haematology, Royal Hospital for Sick Children, Glasgow, Scotland, UK
Rienk Tamminga
Pediatric Oncology/Hematology, Beatrix Children’s Hospital/UMCG, Groningen, The Netherlands;Dutch Childhood Oncology Group, The Hague, The Netherlands
Jonas Abrahamsson
NOPHO, Department of Pediatrics, Queen Silvia’s Children’s Hospital, Göteborg, Sweden
Shau-Yin Ha
Hong Kong Paediatric Haematology & Oncology Study Group, c/o Department of Paediatrics & Adolescent Medicine, Queen Mary Hospital, Hong Kong, China
Henrik Hasle
NOPHO; Department of Pediatrics, Aarhus University Hospital Skejby, Denmark
Alexey Maschan
Research Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russia
Yves Bertrand
FRALLE/CLCG, c/o Institut d’Hématologie et d’Oncologie Pédiatrique, Lyon, France
BFM-AML Group, Hannover, c/o Pediatric Hematology/Oncology, Hannover Medical High School, Germany
Bassem Razzouk
St. Jude’s Children Research Hospital, Memphis, TN, USA, c/o Children’s Center For Cancer and Blood Diseases, Peyton Manning Children’s Hospital at St. Vincent, Indianapolis, IN, USA
Carmelo Rizzari
AIEOP, c/o Department of Pediatrics, Hospital S. Gerardo, Monza, Italy
Petr Smisek
CPH, c/o Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine and University Hospital Motol, Charles University Prague, Czech Republic
Owen P. Smith
UK CCLG; c/o Department of Haematology & Oncology, Our Lady’s Children’s Hospital, Dublin, Ireland
Batia Stark
Center of Pediatric Hematology/Oncology, Schneider Children’s Medical Center of Israel, Petah Tikva, Israel
Dirk Reinhardt
BFM-AML Group, Hannover, c/o Pediatric Hematology/Oncology, Hannover Medical High School, Germany
Gertjan L. Kaspers
Pediatric Oncology/Hematology, VU University Medical Center, Amsterdam, The Netherlands;Dutch Childhood Oncology Group, The Hague, The Netherlands
The prognostic significance of early response to treatment has not been reported in relapsed pediatric acute myeloid leukemia. In order to identify an early and easily applicable prognostic factor allowing subsequent treatment modifications, we assessed leukemic blast counts in the bone marrow by morphology on days 15 and 28 after first reinduction in 338 patients of the international Relapsed-AML2001/01 trial. Both day 15 and day 28 status was classified as good (≤20% leukemic blasts) in 77% of patients. The correlation between day 15 and 28 blast percentages was significant, but not strong (Spearman correlation coefficient = 0.49, P20% had 4-year probabilities of survival of 52%±3% versus 36%±10% versus 21%±9% versus 14%±4%, respectively, P
